University Hospital Schleswig-Holstein
uksh.deTotal trials
159
Active
26
Phase 3
6
Total enrollment
47,211
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 19 of 19 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Mirikizumab | — | — | — | — | — | 1 | |
| Azathioprine | — | — | — | — | — | 1 | |
| 5-Fluorouracil | — | — | — | — | — | 1 | |
| Leucovorin | — | — | — | — | — | 1 | |
| Oxaliplatin | — | — | — | — | — | 1 | |
| Docetaxel | — | — | — | — | — | 1 | |
| Carboplatin | — | — | — | — | — | 1 | |
| Paclitaxel | — | — | — | — | — | 1 | |
| Low-Dose CICR-NAM | — | — | — | — | — | 1 | |
| High-Dose CICR-NAM | — | — | — | — | — | 1 | |
| 0 g/d CICR-NAM | — | — | — | — | — | 1 | |
| Open-Label | — | — | — | — | — | 1 | |
| controlled-ileal-release nicotinic acid as multiple dose 100 mg/day | — | — | — | — | — | 1 | |
| controlled-ileal-release nicotinic acid as multiple dose 200 mg/day | — | — | — | — | — | 1 | |
| controlled-ileal-release nicotinic acid as multiple dose placebo | — | — | — | — | — | 1 | |
| Cannabisextrakt Avextra 10/10 Lösung | — | — | — | — | — | 1 | |
| Tildrakizumab | — | — | — | — | — | 1 | |
| tralokinumab | — | — | — | — | — | 1 | |
| Topical and systemic drugs | — | — | — | — | — | 1 |
Next readouts
- 2024-05-01
- 2024-12-31
- 2026-11-30
- 2027-10
- 2027-10-31
- 2028-03
- 2028-05-01
- 2032-04-30
Top conditions
- Hypothermia6
- Renal Transplantation5
- Pain5
- Hemodynamics4
- Psoriasis3
- Burn Injury3
- Acute Wound3
- Chronic Wound3
Frequently asked questions about University Hospital Schleswig-Holstein
- How many clinical trials does University Hospital Schleswig-Holstein have on ClinicalTrials.gov?
- University Hospital Schleswig-Holstein is listed as the lead sponsor on 159 clinical trials in ClinicalTrials.gov, 26 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University Hospital Schleswig-Holstein's trials are in Phase 3?
- 6 of University Hospital Schleswig-Holstein's trials are in Phase 3, spread across 19 active drug programs.
- What therapeutic areas does University Hospital Schleswig-Holstein focus on?
- University Hospital Schleswig-Holstein's most-studied conditions on ClinicalTrials.gov are Hypothermia, Renal Transplantation, Pain, Hemodynamics, Psoriasis.
- When are University Hospital Schleswig-Holstein's next clinical trial readouts?
- University Hospital Schleswig-Holstein has 8 upcoming primary-completion readouts tracked here; the soonest is “Perioperative Chemotherapy Compared To Neoadjuvant Chemoradiation in Patients With Adenocarcinoma of the Esophagus”, expected around 2024-05-01.